Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

18.30USD
13 Dec 2017
Change (% chg)

$0.41 (+2.29%)
Prev Close
$17.89
Open
$17.89
Day's High
$18.51
Day's Low
$17.74
Volume
72,679
Avg. Vol
64,284
52-wk High
$24.85
52-wk Low
$11.74

Select another date:

Tue, Dec 12 2017

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

BRIEF-CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs

* CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs

BRIEF-Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​

* Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​ Source text: (http://bit.ly/2jeQFaT) Further company coverage:

BRIEF-CRISPR Therapeutics announces third quarter results

* CRISPR Therapeutics announces third quarter 2017 financial results and provides business update

BRIEF-Merck KGaA: Canadian patent office to grant patent application for CRISPR technology

* MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY

BRIEF-CRISPR Therapeutics promotes Samarth Kulkarni to CEO

* CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer

BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

* Crispr Therapeutics announces second quarter 2017 financial results and provides business update

BRIEF-Crispr Therapeutics intellia therapeutics, Caribou Biosciences, ERS Genomics announce Appellate Brief seeking reversal of patent decision on Crispr/Cas9 gene editing

* Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences, ERS Genomics announce appellate brief seeking reversal of patent decision on crispr/cas9 gene editing

BRIEF-Crispr Therapeutics, Neon Therapeutics enter research collaboration​

* Crispr Therapeutics AG - ‍co, Neon Therapeutics enter research collaboration​

Select another date: